The antigen-specific CD8+ T cell repertoire in unimmunized mice includes memory phenotype cells bearing markers of homeostatic expansion C Haluszczak, AD Akue, SE Hamilton, LDS Johnson, L Pujanauski, ... Journal of Experimental Medicine 206 (2), 435-448, 2009 | 438 | 2009 |
TTI-621 (SIRPαFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding PS Petrova, NN Viller, M Wong, X Pang, GHY Lin, K Dodge, V Chai, ... Clinical cancer research 23 (4), 1068-1079, 2017 | 257 | 2017 |
Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies SM Ansell, MB Maris, AM Lesokhin, RW Chen, IW Flinn, A Sawas, ... Clinical Cancer Research 27 (8), 2190-2199, 2021 | 134 | 2021 |
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma OO Oluwole, K Bouabdallah, J Muñoz, S De Guibert, JM Vose, NL Bartlett, ... British journal of haematology 194 (4), 690-700, 2021 | 103 | 2021 |
Targeting CD47 in Sézary syndrome with SIRPαFc LDS Johnson, S Banerjee, O Kruglov, NN Viller, SM Horwitz, A Lesokhin, ... Blood advances 3 (7), 1145-1153, 2019 | 87 | 2019 |
A chronic need for IL-21 LDS Johnson, SC Jameson Science 324 (5934), 1525-1526, 2009 | 53 | 2009 |
TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets GHY Lin, V Chai, V Lee, K Dodge, T Truong, M Wong, LD Johnson, ... PloS one 12 (10), e0187262, 2017 | 50 | 2017 |
Quantification of a Proteotypic Peptide from Protein C Inhibitor by Liquid Chromatography–Free SISCAPA-MALDI Mass Spectrometry: Application to Identification of Recurrence of … M Razavi, LDS Johnson, JJ Lum, G Kruppa, NL Anderson, TW Pearson Clinical chemistry 59 (10), 1514-1522, 2013 | 50 | 2013 |
Histidine Rich Glycoprotein and Cancer: A Multi-faceted Relationship LDS Johnson, HA Goubran, RR Kotb Anticancer Research 34 (2), 593-603, 2014 | 43 | 2014 |
A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed or refractory hematologic malignancies S Ansell, RW Chen, IW Flinn, MB Maris, OA O'Connor, LDS Johnson, ... Blood 128 (22), 1812, 2016 | 40 | 2016 |
Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines E Tran, JS Nielsen, DA Wick, AV Ng, LDS Johnson, NJ Nesslinger, ... PLoS One 5 (12), e15625, 2010 | 36 | 2010 |
TGF-β sensitivity restrains CD8+ T cell homeostatic proliferation by enforcing sensitivity to IL-7 and IL-15 LDS Johnson, SC Jameson Public Library of Science 7 (8), e42268, 2012 | 29 | 2012 |
A single direct intratumoral injection of TTI-621 (SIRPαFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Preliminary … C Querfeld, J Thompson, M Taylor, R Pillai, LDS Johnson, T Catalano, ... Blood 130, 4076, 2017 | 28 | 2017 |
Negative regulators in homeostasis of naive peripheral T cells JF Modiano, LDS Johnson, D Bellgrau Immunologic research 41, 137-153, 2008 | 28 | 2008 |
Blockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy R Uger, L Johnson Expert Opinion on Biological Therapy 20 (1), 5-8, 2020 | 27 | 2020 |
Self-specific CD8+ T cells maintain a semi-naive state following lymphopenia-induced proliferation LDS Johnson, SC Jameson The Journal of Immunology 184 (10), 5604-5611, 2010 | 21 | 2010 |
TTI-622 (SIRPα-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with antitumor antibodies … GHY Lin, NN Viller, M Chabonneau, L Brinen, T Mutukura, K Dodge, ... Cancer Research 78 (13_Supplement), 2709-2709, 2018 | 12 | 2018 |
TTI-621 (SIRPαFc), an immune checkpoint inhibitor blocking the CD47 “do not eat” signal, induces objective responses in patients with advanced, relapsed/refractory diffuse … SM Ansell, IW Flinn, MB Maris, OA O'Connor, A Lesokhin, AS Advani, ... Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 4116 …, 2017 | 12 | 2017 |
Intralesional administration of the CD47 antagonist TTI-621 (SIRPαFc) induces responses in both injected and non-injected lesions in patients with relapsed/refractory mycosis … C Querfeld, J Thompson, MH Taylor, R Pillai, LDS Johnson, T Catalano, ... Blood 132, 1653, 2018 | 10 | 2018 |
Intralesional injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and … C Querfeld, JA Thompson, M Taylor, R Pillai, LDS Johnson, T Catalano, ... European Journal of Cancer 101, S34, 2018 | 10 | 2018 |